Cochrane Abstracts
Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation: Cochrane systematic review
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Mycophenolate Mofetil Versus Methotrexate for Prevention of Graft-versus-host Disease in People Receiving Allogeneic Hematopoietic Stem Cell Transplantation: Cochrane Systematic Review." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/439289/all/Mycophenolate_mofetil_versus_methotrexate_for_prevention_of_graft_versus_host_disease_in_people_receiving_allogeneic_hematopoietic_stem_cell_transplantation:_Cochrane_systematic_review.
Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation: Cochrane systematic review. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/439289/all/Mycophenolate_mofetil_versus_methotrexate_for_prevention_of_graft_versus_host_disease_in_people_receiving_allogeneic_hematopoietic_stem_cell_transplantation:_Cochrane_systematic_review. Accessed March 17, 2025.
Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation: Cochrane systematic review. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/439289/all/Mycophenolate_mofetil_versus_methotrexate_for_prevention_of_graft_versus_host_disease_in_people_receiving_allogeneic_hematopoietic_stem_cell_transplantation:_Cochrane_systematic_review
Mycophenolate Mofetil Versus Methotrexate for Prevention of Graft-versus-host Disease in People Receiving Allogeneic Hematopoietic Stem Cell Transplantation: Cochrane Systematic Review [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 March 17]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/439289/all/Mycophenolate_mofetil_versus_methotrexate_for_prevention_of_graft_versus_host_disease_in_people_receiving_allogeneic_hematopoietic_stem_cell_transplantation:_Cochrane_systematic_review.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation: Cochrane systematic review
ID - 439289
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/439289/all/Mycophenolate_mofetil_versus_methotrexate_for_prevention_of_graft_versus_host_disease_in_people_receiving_allogeneic_hematopoietic_stem_cell_transplantation:_Cochrane_systematic_review
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
